Skip to main content

Spotlight on Atomoxetine in Adults with Attention-Deficit Hyperactivity Disorder

CNS Drugs volume 18, pages 397–401 (2004)Cite this article

Abstract

Atomoxetine (Strattera™) is a selective noradrenaline (norepinephrine) reuptake inhibitor and nonstimulant that has shown greater efficacy than placebo in attention-deficit hyperactivity disorder (ADHD) in adults. In two large, well controlled, 10-week trials in adults with ADHD, improvements in ADHD symptoms, as assessed by investigator- and patient-rated scores, were greater with oral atomoxetine (60, 90 or 120 mg/day) than with placebo. Mean reductions in the total ADHD symptom score on the investigator-rated Conners’ Adult ADHD Rating Scale (CAARS) in atomoxetine versus placebo recipients were 28.3% versus 18.1% and 30.1% versus 19.6%, respectively. Mean reductions in the scores on the Clinician Global Impression of Severity Scale, patient-rated CAARS and Wender-Reimherr Adult Attention Deficit Disorder Scale were also significantly greater with atomoxetine than with placebo. Continued efficacy was demonstrated in a noncomparative, 34-week extension phase.

Atomoxetine was generally well tolerated in clinical trials; withdrawal rates due to adverse events in atomoxetineversus placebo-treated patients participating in the two major trials were 7.8% versus 4.3% and 9.3% versus 2.4% (p < 0.05 for the latter trial). Adverse events reported significantly more frequently with atomoxetine than placebo included dry mouth, insomnia, nausea, decreased appetite, constipation, dizziness, sweating, dysuria, sexual problems and palpitations. Modest increases in heart rate and blood pressure were well tolerated and gradually decreased on cessation of treatment. Atomoxetine was not associated with QT interval prolongation.

Atomoxetine can be administered once or twice daily. Its subjective-effects profile is different to that of methylphenidate and atomoxetine is not associated with abuse or diversion; it is therefore not a controlled substance in the US. This also means repeat prescriptions during long-term treatment can be more conveniently processed.

Conclusion: Atomoxetine is an effective and generally well tolerated treatment for adults with ADHD. It is a nonstimulant and is the first ADHD treatment to be approved specifically for adult use based on its efficacy in well controlled adult trials. It can be administered as a single daily dose or split into two evenly divided doses. It carries negligible risk of abuse or diversion and is not a controlled substance. Atomoxetine is a valuable new treatment option for adults with ADHD and is particularly useful in patients who are at risk for substance abuse or who do not wish to take a controlled substance.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Stahl SM. Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry 2003 Feb; 64(2): 110–1

    PubMed  Article  Google Scholar 

  2. Gehlert DR, Schober DA, Gackenheimer SL. Comparison of (R)-[3H]tomoxetine and (R/S)-[3H]nisoxetine binding in rat brain. J Neurochem 1995 Jun; 64(6): 2792–800

    PubMed  Article  CAS  Google Scholar 

  3. Wong DT, Penny G, Threlkeld KL, et al. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther 1982 Jul; 222(1): 61–5

    PubMed  CAS  Google Scholar 

  4. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52(12): 1023–9

    PubMed  Article  CAS  Google Scholar 

  5. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002 Nov; 27(5): 699–711

    PubMed  Article  CAS  Google Scholar 

  6. Gehlert DR, Gackenheimer SL, Robertson DW. Localization of rat brain binding sites for [3H] tomoxetine an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci Lett 1993 Jul 23; 157(2): 203–6

    PubMed  Article  CAS  Google Scholar 

  7. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) 1994 May; 114(4): 559–65

    Article  CAS  Google Scholar 

  8. Fuller RW, Hemrick-Leucke SK. Antagonism by tomoxetine of the depletion of norepinephrine and epinephrine in rat brain by a-methyl-m-tyrosine. Res Commun Chem Pathol Pharmacol 1983 Jul; 41(1): 169–72

    PubMed  CAS  Google Scholar 

  9. Zerbe RL, Rowe H, Enas GG, et al. Clinical pharmacology of tomoxetine, a potential antidepressant. J Pharmacol Exp Ther 1985 Jan; 232(1): 139–43

    PubMed  CAS  Google Scholar 

  10. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003 Jan 15; 53(2): 112–20

    PubMed  Article  CAS  Google Scholar 

  11. Adler L, Spencer T, Sutton V, et al. Dose and time response of atomoxetine use in adult ADHD [poster]. American Academy of Child and Adolescent Psychiatry (AACAP); 2003 Oct 14–19; Miami

  12. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002 Jul 1; 67(2): 149–56

    PubMed  Article  CAS  Google Scholar 

  13. Eli Lilly and Company. Indianapolis. Strattera (R) (atomoxetine HC1) [online]. Available from URL: http://www.strattera.com [Accessed 2003 Jul 28]

  14. Sauer JM, Ponsler GD, Mattiuz EL, et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 2003 Jan; 31(1): 98–107

    PubMed  Article  CAS  Google Scholar 

  15. Chalon SA, Desager JP, Desante KA, et al. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther 2003 Mar; 73(3): 178–91

    PubMed  Article  CAS  Google Scholar 

  16. Belle DJ, Ernest CS, Sauer JM, et al. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 2002 Nov; 42(11): 1219–27

    PubMed  Article  CAS  Google Scholar 

  17. Reimherr FW, Strong RE, Dawson WH, et al. Emotional dysregulation in ADHD and response to atomoxetine [abstract no. NR640]. American Psychiatric Association 2003 Annual Meeting; New Research Abstracts, 156th Annual Meeting; 2003 May 17–22; San Francisco

  18. Adler LA, Spencer TJ, Reimherr FW, et al. Efficacy and safety of atomoxetine in long-term, open-label treatment of adults with ADHD [abstract no. NR645 plus poster]. American Psychiatric Association 2003 Annual Meeting; New Research Abstracts, 156th Annual Meeting; 2003 May 17–22; San Francisco

  19. Wernicke FJ, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26(10): 729–40

    PubMed  Article  CAS  Google Scholar 

  20. Eli Lilly and Company, 2003. (Data on file)

Download references

Acknowledgements

The full text article in Drugs 2003; 64 (2): 205-222 was reviewed by: P.J. Ambrosini, Eastern Pennsylvania Psychiatric Institute, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA; J. Elia, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA; J.H. Newcorn, Department of Psychiatry, Mount Sinai Medical Center, New York, New York, USA; F. Reimherr, Department of Psychiatry, University of Utah Health Sciences Center, Salt Lake City, Utah, USA; M. Weiss, Children’s and Women’s Health Centre of British Columbia, Vancouver, British Columbia, Canada.

Author information

Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Dene Simpson & Greg L. Plosker

Authors
  1. Dene Simpson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Greg L. Plosker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dene Simpson.

Additional information

This Spotlight is derived from abstract and summary text of an Adis Drug Evaluation originally published in full in Drugs 2003; 64 (2): 205–222. Reviewers of the original full text article are listed in the Acknowledgments section.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Simpson, D., Plosker, G.L. Spotlight on Atomoxetine in Adults with Attention-Deficit Hyperactivity Disorder. CNS Drugs 18, 397–401 (2004). https://doi.org/10.2165/00023210-200418060-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200418060-00011

Keywords

  • Paroxetine
  • Methylphenidate
  • Atomoxetine
  • CYP2D6 Inhibitor
  • Narrow Angle Glaucoma